NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.

This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

More From The Market Online

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.

FDA grants full approval to Pfizer’s colorectal cancer treatment

The FDA granted full approval to Pfizer’s (NYSE:PFE) BRAFTOVI + cetuximab + fluorouracil based chemotherapy for adults.